Abstract 4034: A potent and highly selective irreversible HER2 inhibitor for treating HER2-driven cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4034
Abstract: HER2 amplification and mutations occur frequently in multiple human cancers, including breast, ovarian, gastric and lung cancers. Despite HER2 being one of the earliest oncogenic drivers discovered, HER2 inhibitors have had limited clinical success compared… read more here.
Keywords: ent; her2; inhibitor; driven cancers ... See more keywords